Ascendis Health CEO, Thomas Thomsen said, “We are pleased to complement our primary listing on the JSE with the secondary listing on A2X. We see the secondary listing as an opportunity to attract potential new investors through the lower-cost trading structure of A2X and broaden our shareholder base. There is no cost to the secondary listing or any additional regulatory compliance.”

Categories: